BIOMAT Database Logo BIOMAT Database Logo

Characterization of insulin-like growth factor II (IGF-II) and IGF binding proteins in patients with non-islet-cell tumor hypoglycemia. 1993

I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical College, Tokyo, Japan.

Insulin-like growth factor II (IGF-II) in serum and tumor extracts from five patients with non-islet-cell tumor hypoglycemia (NICTH) has been characterized. These tumors contained large quantities of IGF-II (2.4-14.2 micrograms/g tissues). The serum IGF-II levels in four of five patients were a little high and the serum IGF-I levels in five patients were low. The serum IGF-II/IGF-I ratios in these patients ranged from 24.1 to 64.2, and the values were significantly greater than those in normal subjects (1.7-7.1). When the sera were gel-filtered on a Sephacryl S-200 column under neutral conditions, the proportion of the free form of IGF-II was not increased. However, in four of five patients, an abnormal IGF-II-IGF binding protein complex was found. When serum IGF binding proteins (IGFBPs) were analyzed by Western ligand blotting, serum IGFBP-2 increased in these patients. When the tumor extracts and sera were gel-filtered on a Biogel P-60 column under acidic conditions, the majority of IGF-II in these sera was a big form of IGF-II. As compared to authentic IGF-II, insulin receptor reactivities and IGF-II receptor reactivities of tumor extracted IGF-II increased in two of three patients. These data indicate that in patients with NICTH, heterogenous IGF-II is produced in respect of size and bioactivities, and that the characteristics of IGF binding protein are altered. Thus, to find IGF-II producing tumors among extrapancreatic tumors associated with hypoglycemia, the quality of IGF-II as well as the quantity should be studied.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D005260 Female Females

Related Publications

I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Role of insulin-like growth factor II and IGF binding proteins in extrapancreatic tumor hypoglycemia.
January 1994, Hormone research,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Insulin-like growth factors and non-islet cell tumor hypoglycemia.
September 1993, Metabolism: clinical and experimental,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.
December 1981, The New England journal of medicine,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.
May 1982, The New England journal of medicine,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
July 2005, The Journal of clinical endocrinology and metabolism,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Insulin-like growth factor-II (IGF-II) and IGF binding proteins in human endometrium.
January 1991, Annals of the New York Academy of Sciences,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
A case of gastric cancer with non-islet cell tumor hypoglycemia detected by insulin-like growth factor II.
August 2010, Pathology international,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Gastric neuroendocrine carcinoma with non-islet cell tumor hypoglycemia associated with enhanced production of insulin-like growth factor II.
January 2013, Internal medicine (Tokyo, Japan),
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Insulin-like growth factor (IGF)-II/IGF-binding proteins in constitutionally tall children.
April 2003, The Journal of clinical endocrinology and metabolism,
I Fukuda, and N Hizuka, and K Takano, and K Asakawa-Yasumoto, and K Shizume, and H Demura
Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors.
September 1989, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!